Germline POT1 Variants in a Pan-Cancer Cohort
JCO Precision Oncology · 2025
DOI: 10.1200/po-24-00946 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Pamela L Brock und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Human Genetics, The Ohio State University College of Medicine, Comprehensive Cancer Center, Columbus, OH. Hauptthemen laut MEDLINE: Neoplasms, Germ-Line Mutation, Telomere-Binding Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Germline likely pathogenic and pathogenic variants (LPV/PVs) in POT1 have been associated with an increased risk of various cancers including angiosarcoma, melanoma, glioma, thyroid cancer, and chronic lymphocytic leukemia (CLL). However, to date, most of the published data regarding POT1 PVs involve cohorts of patients selected for specific cancer types, or stem from commercial laboratory cohorts from patients selected for germline clinical testing, which may cause ascertainment biases. The objective was to identify germline POT1 variants in a pan-cancer cohort and describe the associated phenotypes. METHODS Germline exome data available for 19,315 patients with cancer from the Oncology Research Information Exchange Network (ORIEN) were assessed for POT1 LPV/PV. Data regarding cancer diagnoses were obtained for those with and without POT1 variants. Associations were assessed. RESULTS POT1 LPV/PVs were identified in 23 patients. The cancer types seen in more than one patient include CLL (n = 7), papillary thyroid cancer (PTC, n = 5), colorectal cancer (n = 3), lung cancer (n = 3), glioblastoma (n = 2), and neuroendocrine tumors (n = 2). Compared with POT1 -negative patients, those with POT1 LPV/PVs were 5.5-fold more likely to be diagnosed with PTC (95% CI, 1.9 to 15.1; P = .004) and 16.6-fold more likely to be diagnosed with CLL (95% CI, 6.4 to 41.9; P < .001). Patients with POT1 LPV/PVs had a younger median age of first cancer diagnosis compared with POT1 -negative patients ( P = .008). CONCLUSION To our knowledge, this study is the largest investigation of POT1 germline variants in a pan-cancer cohort. We identify and confirm specific associations with CLL and PTC in this cohort. Differences in results between analysis of largely unselected cohorts compared with clinical testing cohorts highlight the need to study gene-cancer associations in more unselected populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Human Genetics, The Ohio State University College of Medicine, Comprehensive Cancer Center, Columbus, OH.
- Maternal Fetal Medicine, Legacy Health, Portland, OR.
- Department of Molecular Medicine and Therapeutics, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
- Department of Medical Oncology, Rutgers Cancer Institute, New Brunswick, NJ.
- Department of Pathology, Moffitt Cancer Center, Tampa, FL.
- Holden Comprehensive Cancer Center, University of Iowa Health Care, Iowa City, IA.
ORCID-Profile: Pamela L Brock, Sandya Liyanarachchi, Lindsey Byrne, Pat Gulhati, J Kevin Hicks, Carlos H F Chan, Leigh Anne Stout, Whitney Maxwell, Juvianee Estrada-Veras, Bodour Salhia, Mohamed H Abdel-Rahman
Förderung
- NCI NIH HHS
Zitieren
APA
Brock, P. L., Webster, M., Liyanarachchi, S., Byrne, L., Hedges, D. J., Gulhati, P., Hicks, J. K., Chan, C. H. F., Onel, K., Stout, L. A., Maxwell, W., Pickarski, J. C., Estrada-Veras, J., Salhia, B., Axell, L., Holman, L. L., Abdel-Rahman, M. H., & Ringel, M. D. (2025). Germline POT1 Variants in a Pan-Cancer Cohort. JCO Precision Oncology. https://doi.org/10.1200/po-24-00946
Vancouver
Brock PL, Webster M, Liyanarachchi S, Byrne L, Hedges DJ, Gulhati P, et al. Germline POT1 Variants in a Pan-Cancer Cohort. JCO Precision Oncology. 2025. doi:10.1200/po-24-00946
BibTeX
@article{Brock2025,
author = {Brock, Pamela L and Webster, Morgan and Liyanarachchi, Sandya and Byrne, Lindsey and Hedges, Dale J and Gulhati, Pat and Hicks, J Kevin and Chan, Carlos H F and Onel, Kenan and Stout, Leigh Anne and Maxwell, Whitney and Pickarski, Justine Cooper and Estrada-Veras, Juvianee and Salhia, Bodour and Axell, Lisen and Holman, Laura L and Abdel-Rahman, Mohamed H and Ringel, Matthew D},
title = {Germline POT1 Variants in a Pan-Cancer Cohort},
journal = {JCO Precision Oncology},
year = {2025},
doi = {10.1200/po-24-00946}
}
EUVIMED